NSPR · InspireMD, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 27, 2021; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted gross margin non-GAAP | 34.1% | first quarter of 2026 | — |
| adjusted gross profit non-GAAP | $1.2M | first quarter of 2026 | — |
| U.S. hospitals and integrated delivery networks | 100 | since launch | — |
| cumulative carotid procedures utilizing CGuard Prime | 500 | since launch through Q4 FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NSPR
this stock
InspireMD, Inc.
|
$45.67M | -44.8% | -18.0% | — | 0.2% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 27, 2021; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NSPR | +32.6% | +40.3% | -46.0% | +51.1% | -44.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +32.2% | +35.9% | -59.8% | +47.2% | -58.7% |